03.18.14
Cardiva Medical, Inc. has appointed Randy Hubbell as chief commercial officer. He will be responsible for expanding commercialization efforts for Cardiva's portfolio of devices for femoral vascular closure including the Vascade Vascular Closure System and the Catalyst closure wire.
"Randy brings to Cardiva a unique blend of commercial expertise and strategic marketing that will prove invaluable to Cardiva," President/CEO Charles Maroney said. "We are confident in Randy's ability to lead us."
Hubbell has more than 20 years of sales and strategic marketing experience in the medical device business. Prior to joining Cardiva, Randy served as a senior sales and marketing executive at Johnson & Johnson for 14 years. He was vice president of Worldwide Marketing at Ethicon Biosurgery from 2008 to 2013, where he was responsible for the global commercialization of hemostasis and surgical sealant products. Before that, he was worldwide vice president in the Pharmaceuticals Group Strategic Marketing. Hubbell joined Johnson & Johnson Cordis in 2001 as director of U.S. Stent Marketing and helped launch the first drug-eluting stent, Cypher.
Before he worked at Johnson & Johnson, Hubbell was vice president of Sales and Marketing at Enmed and director of Sales and Marketing at NxStage. He began his career in medical devices at Boston Scientific Corp. He holds a B.S. in computer science from Tulane University in New Orleans, La., and an M.B.A. from Loyola University of the South (also in New Orleans).
"I believe Cardiva offers the best solution to current shortcomings in vascular closure procedures and is poised to change the way doctors and hospitals treat their patients," Hubbell said. "I am excited for the opportunity to bring this technology to patient care."
Cardiva Medical, Inc. is a privately held developer of vascular closure technology designed to help the body heal itself following percutaneous catheterization procedures. The company is based in Sunnyvale, Calif.
"Randy brings to Cardiva a unique blend of commercial expertise and strategic marketing that will prove invaluable to Cardiva," President/CEO Charles Maroney said. "We are confident in Randy's ability to lead us."
Hubbell has more than 20 years of sales and strategic marketing experience in the medical device business. Prior to joining Cardiva, Randy served as a senior sales and marketing executive at Johnson & Johnson for 14 years. He was vice president of Worldwide Marketing at Ethicon Biosurgery from 2008 to 2013, where he was responsible for the global commercialization of hemostasis and surgical sealant products. Before that, he was worldwide vice president in the Pharmaceuticals Group Strategic Marketing. Hubbell joined Johnson & Johnson Cordis in 2001 as director of U.S. Stent Marketing and helped launch the first drug-eluting stent, Cypher.
Before he worked at Johnson & Johnson, Hubbell was vice president of Sales and Marketing at Enmed and director of Sales and Marketing at NxStage. He began his career in medical devices at Boston Scientific Corp. He holds a B.S. in computer science from Tulane University in New Orleans, La., and an M.B.A. from Loyola University of the South (also in New Orleans).
"I believe Cardiva offers the best solution to current shortcomings in vascular closure procedures and is poised to change the way doctors and hospitals treat their patients," Hubbell said. "I am excited for the opportunity to bring this technology to patient care."
Cardiva Medical, Inc. is a privately held developer of vascular closure technology designed to help the body heal itself following percutaneous catheterization procedures. The company is based in Sunnyvale, Calif.